Literature DB >> 26884178

Deep phenotyping of 89 xeroderma pigmentosum patients reveals unexpected heterogeneity dependent on the precise molecular defect.

Hiva Fassihi1, Mieran Sethi2, Heather Fawcett3, Jonathan Wing3, Natalie Chandler4, Shehla Mohammed4, Emma Craythorne5, Ana M S Morley5, Rongxuan Lim5, Sally Turner5, Tanya Henshaw5, Isabel Garrood5, Paola Giunti6, Tammy Hedderly5, Adesoji Abiona5, Harsha Naik5, Gemma Harrop5, David McGibbon5, Nicolaas G J Jaspers7, Elena Botta8, Tiziana Nardo8, Miria Stefanini8, Antony R Young2, Robert P E Sarkany5, Alan R Lehmann9.   

Abstract

Xeroderma pigmentosum (XP) is a rare DNA repair disorder characterized by increased susceptibility to UV radiation (UVR)-induced skin pigmentation, skin cancers, ocular surface disease, and, in some patients, sunburn and neurological degeneration. Genetically, it is assigned to eight complementation groups (XP-A to -G and variant). For the last 5 y, the UK national multidisciplinary XP service has provided follow-up for 89 XP patients, representing most of the XP patients in the United Kingdom. Causative mutations, DNA repair levels, and more than 60 clinical variables relating to dermatology, ophthalmology, and neurology have been measured, using scoring systems to categorize disease severity. This deep phenotyping has revealed unanticipated heterogeneity of clinical features, between and within complementation groups. Skin cancer is most common in XP-C, XP-E, and XP-V patients, previously considered to be the milder groups based on cellular analyses. These patients have normal sunburn reactions and are therefore diagnosed later and are less likely to adhere to UVR protection. XP-C patients are specifically hypersensitive to ocular damage, and XP-F and XP-G patients appear to be much less susceptible to skin cancer than other XP groups. Within XP groups, different mutations confer susceptibility or resistance to neurological damage. Our findings on this large cohort of XP patients under long-term follow-up reveal that XP is more heterogeneous than has previously been appreciated. Our data now enable provision of personalized prognostic information and management advice for each XP patient, as well as providing new insights into the functions of the XP proteins.

Entities:  

Keywords:  UV radiation; neurodegeneration; nucleotide excision repair; ocular disease; skin cancer

Mesh:

Year:  2016        PMID: 26884178      PMCID: PMC4780618          DOI: 10.1073/pnas.1519444113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  55 in total

1.  Differences in clinical phenotype among patients with XP complementation group D: 3D structure and ATP-docking of XPD in silico.

Authors:  Eiji Nakano; Ryusuke Ono; Taro Masaki; Seiji Takeuchi; Yutaka Takaoka; Eiichi Maeda; Chikako Nishigori
Journal:  J Invest Dermatol       Date:  2014-01-13       Impact factor: 8.551

2.  Patients with xeroderma pigmentosum complementation groups C, E and V do not have abnormal sunburn reactions.

Authors:  M Sethi; A R Lehmann; H Fawcett; M Stefanini; N Jaspers; K Mullard; S Turner; A Robson; D McGibbon; R Sarkany; H Fassihi
Journal:  Br J Dermatol       Date:  2013-12       Impact factor: 9.302

3.  Malfunction of nuclease ERCC1-XPF results in diverse clinical manifestations and causes Cockayne syndrome, xeroderma pigmentosum, and Fanconi anemia.

Authors:  Kazuya Kashiyama; Yuka Nakazawa; Daniela T Pilz; Chaowan Guo; Mayuko Shimada; Kensaku Sasaki; Heather Fawcett; Jonathan F Wing; Susan O Lewin; Lucinda Carr; Tao-Sheng Li; Koh-ichiro Yoshiura; Atsushi Utani; Akiyoshi Hirano; Shunichi Yamashita; Danielle Greenblatt; Tiziana Nardo; Miria Stefanini; David McGibbon; Robert Sarkany; Hiva Fassihi; Yoshito Takahashi; Yuji Nagayama; Norisato Mitsutake; Alan R Lehmann; Tomoo Ogi
Journal:  Am J Hum Genet       Date:  2013-04-25       Impact factor: 11.025

4.  Xeroderma pigmentosum complementation group G patient with a novel homozygous missense mutation and no neurological abnormalities.

Authors:  Shinichi Moriwaki; Masahiro Takigawa; Naoya Igarashi; Yayoi Nagai; Hiroo Amano; Osamu Ishikawa; Sikandar G Khan; Kenneth H Kraemer
Journal:  Exp Dermatol       Date:  2012-04       Impact factor: 3.960

5.  Constructive rescue of TFIIH instability by an alternative isoform of XPD derived from a mutated XPD allele in mild but not severe XP-D/CS.

Authors:  Katsuyoshi Horibata; Sayaka Kono; Chie Ishigami; Xue Zhang; Madoka Aizawa; Yuko Kako; Takuma Ishii; Rika Kosaki; Masafumi Saijo; Kiyoji Tanaka
Journal:  J Hum Genet       Date:  2015-02-26       Impact factor: 3.172

6.  High prevalence of the point mutation in exon 6 of the xeroderma pigmentosum group A-complementing (XPAC) gene in xeroderma pigmentosum group A patients in Tunisia.

Authors:  C Nishigori; M Zghal; T Yagi; S Imamura; M R Komoun; H Takebe
Journal:  Am J Hum Genet       Date:  1993-11       Impact factor: 11.025

7.  Clinical heterogeneity within xeroderma pigmentosum associated with mutations in the DNA repair and transcription gene ERCC3.

Authors:  W Vermeulen; R J Scott; S Rodgers; H J Müller; J Cole; C F Arlett; W J Kleijer; D Bootsma; J H Hoeijmakers; G Weeda
Journal:  Am J Hum Genet       Date:  1994-02       Impact factor: 11.025

8.  Characterization of three XPG-defective patients identifies three missense mutations that impair repair and transcription.

Authors:  Annika Schäfer; Steffen Schubert; Alexei Gratchev; Christina Seebode; Antje Apel; Petra Laspe; Lars Hofmann; Andreas Ohlenbusch; Toshio Mori; Nobuhiko Kobayashi; Anke Schürer; Michael P Schön; Steffen Emmert
Journal:  J Invest Dermatol       Date:  2013-01-31       Impact factor: 8.551

9.  Mutations in the XPD gene in xeroderma pigmentosum group D cell strains: confirmation of genotype-phenotype correlation.

Authors:  Takehiro Kobayashi; Makoto Uchiyama; Shuhei Fukuro; Kiyoji Tanaka
Journal:  Am J Med Genet       Date:  2002-07-01

10.  A Distinct Genotype of XP Complementation Group A: Surprisingly Mild Phenotype Highly Prevalent in Northern India/Pakistan/Afghanistan.

Authors:  Mieran Sethi; Shaheen Haque; Heather Fawcett; Jonathan F Wing; Natalie Chandler; Shehla Mohammed; Ian M Frayling; Paul G Norris; David McGibbon; Antony R Young; Robert P E Sarkany; Alan R Lehmann; Hiva Fassihi
Journal:  J Invest Dermatol       Date:  2015-12-29       Impact factor: 8.551

View more
  52 in total

1.  Use of Big Data to Estimate Prevalence of Defective DNA Repair Variants in the US Population.

Authors:  Jennifer Pugh; Sikandar G Khan; Deborah Tamura; Alisa M Goldstein; Maria Teresa Landi; John J DiGiovanna; Kenneth H Kraemer
Journal:  JAMA Dermatol       Date:  2019-01-01       Impact factor: 10.282

Review 2.  [Light protection for xeroderma pigmentosum].

Authors:  M Ettinger; M Berneburg
Journal:  Hautarzt       Date:  2017-05       Impact factor: 0.751

Review 3.  Xeroderma pigmentosum: overview of pharmacology and novel therapeutic strategies for neurological symptoms.

Authors:  Rosella Abeti; Anna Zeitlberger; Colm Peelo; Hiva Fassihi; Robert P E Sarkany; Alan R Lehmann; Paola Giunti
Journal:  Br J Pharmacol       Date:  2019-01-23       Impact factor: 8.739

4.  Fanconi anemia with sun-sensitivity caused by a Xeroderma pigmentosum-associated missense mutation in XPF.

Authors:  Isabell Popp; Maqsood Punekar; Nick Telford; Stavros Stivaros; Kate Chandler; Meenakshi Minnis; Anna Castleton; Claire Higham; Louise Hopewell; D Gareth Evans; Anja Raams; Arjan F Theil; Stefan Meyer; Detlev Schindler
Journal:  BMC Med Genet       Date:  2018-01-11       Impact factor: 2.103

5.  Macular and Retinal Nerve Fibre Layer Thinning in Xeroderma Pigmentosum: A Cross-sectional Study.

Authors:  Anna M Gruener; Ana M S Morley
Journal:  Neuroophthalmology       Date:  2018-05-22

Review 6.  Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders.

Authors:  Michael F Walsh; Vivian Y Chang; Wendy K Kohlmann; Hamish S Scott; Christopher Cunniff; Franck Bourdeaut; Jan J Molenaar; Christopher C Porter; John T Sandlund; Sharon E Plon; Lisa L Wang; Sharon A Savage
Journal:  Clin Cancer Res       Date:  2017-06-01       Impact factor: 12.531

Review 7.  Expanding molecular roles of UV-DDB: Shining light on genome stability and cancer.

Authors:  Maria Beecher; Namrata Kumar; Sunbok Jang; Vesna Rapić-Otrin; Bennett Van Houten
Journal:  DNA Repair (Amst)       Date:  2020-04-27

8.  Spironolactone Depletes the XPB Protein and Inhibits DNA Damage Responses in UVB-Irradiated Human Skin.

Authors:  Michael G Kemp; Smita Krishnamurthy; Michael N Kent; David L Schumacher; Priyanka Sharma; Katherine J D A Excoffon; Jeffrey B Travers
Journal:  J Invest Dermatol       Date:  2018-09-15       Impact factor: 8.551

9.  A novel DDB2 mutation causes defective recognition of UV-induced DNA damages and prevalent equine squamous cell carcinoma.

Authors:  Lu Chen; Rebecca R Bellone; Yan Wang; Moriel Singer-Berk; Kaoru Sugasawa; James M Ford; Steven E Artandi
Journal:  DNA Repair (Amst)       Date:  2020-11-12

10.  Reduced levels of prostaglandin I2 synthase: a distinctive feature of the cancer-free trichothiodystrophy.

Authors:  Anita Lombardi; Lavinia Arseni; Roberta Carriero; Emmanuel Compe; Elena Botta; Debora Ferri; Martina Uggè; Giuseppe Biamonti; Fiorenzo A Peverali; Silvia Bione; Donata Orioli
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.